BridgeBio plans $550M convertible notes offering due 2033

2026-01-14 16:09:21 ET

More on BridgeBio Pharma

• BridgeBio Pharma, Inc. (BBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Prepared Remarks Transcript
• BridgeBio Pharma, Inc. (BBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
• BridgeBio Pharma, Inc. (BBIO) Discusses Achondroplasia Pathophysiology, Unmet Needs, and PROPEL 3 Infigratinib Phase 3 Study - Slideshow
• BridgeBio targets 30%+ market share for Attruby while advancing late-stage pipeline and reporting $120.7M Q3 revenue
• BridgeBio succeeds in late-stage encaleret study

Read the full article on Seeking Alpha

For further details see: